Mydriasis Treatment Market By Treatment Type (Pharmaceutical Products, Surgical & Reconstructive Procedures, Symptom-Management Products); By Product Function (Dilation-Inducing Drugs, Intraoperative Dilation-Maintenance Products, Dilation-Reversal Agents, Iris Reconstruction & Artificial Iris Implants); By Application (Diagnostic Eye Examinations, Cataract & Intraocular-Lens Surgery, Retinal & Diabetic Eye Monitoring, Post-Dilation Reversal, Permanent Mydriasis & Iris-Defect Reconstruction); By End User (Optometry Clinics, Ophthalmology Clinics, Ambulatory Surgical Centers, Hospitals); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Mydriasis Treatment Market: Dilation Reversal, Cataract-Surgery Economics, and Iris Reconstruction Shape a Specialized Ophthalmic Market

The Global Mydriasis Treatment Market was valued at USD 692.4 million in 2025 and is projected to reach USD 1,019.3 million by 2032, growing at a CAGR of 5.68%, according to Strategic Market Research.

 

The mydriasis treatment market covers pharmacologic pupil dilation for ophthalmic examinations, maintenance of intraoperative dilation during eye surgery and reversal of drug-induced dilation. A smaller procedural segment treats persistent mydriasis or irregular pupils caused by trauma, iris-sphincter damage, postoperative complications or iris tissue loss.

 

Market demand is driven by routine eye examinations, cataract surgery, post-dilation reversal and iris reconstruction. Benign physiologic anisocoria and naturally large pupils should be excluded from market estimates because they usually do not require treatment.

 

Approximately 100 Million U.S. Dilations Define the Maximum Addressable Event Pool

Opus Genetics estimates that approximately 100 million pharmacologic eye dilations are performed annually in the United States. Routine comprehensive examinations, diabetic retinal surveillance, glaucoma assessment, pediatric cycloplegic examinations, retinal monitoring, and ophthalmic procedures account for most of these events.

The estimate represents dilation encounters rather than unique patients or treated reversal events. Many patients allow tropicamide, phenylephrine, cyclopentolate, atropine, or combination agents to wear off naturally. Others experience little disruption or attend practices that do not stock a reversal drug.

Tropicamide generally reaches peak dilation within approximately 25–30 minutes, while blurred near vision and light sensitivity can persist for several hours. Working adults, caregivers, drivers, digital-screen users, and patients undergoing repeated retinal examinations have the strongest incentive to pay for faster recovery.

Eye-care practices generate recurring demand because they perform dilated examinations continuously, even though individual patients require treatment only periodically. Drug administrations, spray events, bottles, and single-patient-use vials are therefore more useful commercial measures than mydriasis prevalence.

 

RYZUMVI Established a Branded Dilation-Reversal Category

RYZUMVI, or phentolamine ophthalmic solution 0.75%, received FDA approval in September 2023 and was commercially launched by Viatris in April 2024. The indication covers pharmacologically induced mydriasis caused by adrenergic agonists such as phenylephrine, parasympatholytic agents such as tropicamide, or combinations of these drugs. Adults and children aged three years and older are eligible under the approved label.

Phentolamine blocks alpha-1 and alpha-2 adrenergic activity in the iris dilator muscle and reduces pupil diameter without directly stimulating the ciliary muscle. Traditional miotic agents such as pilocarpine affect accommodation and are less suited to routine post-examination reversal in some patients.

MIRA-2 and MIRA-3 enrolled 553 participants. At 90 minutes, approximately 49% and 58% of RYZUMVI-treated participants returned to within 0.2 millimeters of baseline pupil diameter, compared with approximately 7% and 6% in the respective vehicle groups. Among vehicle recipients, 34% and 28% had not returned to baseline after 24 hours. Faster recovery during the first few hours after an examination addresses the period when photophobia, reading difficulty, and screen-use disruption are most noticeable.

Natural recovery remains the main competitive alternative because it carries no additional cost. Providers must identify patients who place enough value on faster recovery to accept another treatment after the examination is complete. Cash-pay adoption depends on affordability, provider explanation, office workflow, inventory management, and point-of-care payment collection.

Opus reported approximately USD 36,000 in RYZUMVI royalties during the first nine months of 2024. Later disclosures continued to describe royalties as a much smaller component of collaboration revenue than research reimbursements. Public filings do not disclose product sales, treated encounters, vials shipped, provider accounts, or cash-pay conversion.

 

Traditional Mydriatics Retain the Largest Examination Volume

Tropicamide remains the preferred short-acting agent for routine dilation, while phenylephrine is added when a larger pupil is needed. Cyclopentolate and atropine provide stronger or longer cycloplegia and are more common in pediatric refraction and selected clinical settings.

Medicare Part D data substantially understate actual use because practices usually purchase bottles and administer drops directly. Only 251 tropicamide claims covering 228 beneficiaries were recorded in 2023. Generic cyclopentolate generated 21,693 claims, while branded Cyclogyl generated another 365 claims.

The combined 22,058 identified cyclopentolate claims represent a retail-pharmacy lower boundary rather than total clinical volume. Office-administered doses are excluded, and some prescriptions relate to cycloplegic examinations or inflammatory eye conditions rather than routine mydriasis.

Broad atropine data are unsuitable for mydriasis sizing because the category includes several formulations and indications. Isopto Atropine generated 979 Medicare Part D claims covering 739 beneficiaries in 2023, but these prescriptions also include cycloplegia and amblyopia management.

 

MYDCOMBI Combined Fixed-Dose Dilation With Microdosed Delivery

MYDCOMBI combines tropicamide 1% and phenylephrine hydrochloride 2.5% in an ophthalmic spray delivered through the Optejet micro-array system. It became the first FDA-approved fixed-dose combination of these drugs in the United States and the first approved product using the Optejet platform. Controlled microdosing and touch-free administration were intended to improve delivery consistency during diagnostic examinations.

Commercial revenue remained limited. Eyenovia reported approximately USD 57,336 in ophthalmic-technology revenue during 2024 and USD 14,720 from ophthalmological products during 2025 before ceasing sales efforts for those products.

Those figures do not disclose MYDCOMBI devices, cartridges, sprays, patients, or provider accounts. Limited uptake despite differentiated delivery indicates that clinical novelty must be supported by reliable manufacturing, adequate financing, broad account coverage, and a clear economic advantage over inexpensive office-stocked drops.

 

OMIDRIA Links Pupil Management Directly to Cataract-Surgery Revenue

Nearly four million cataract procedures are performed annually in the United States. OMIDRIA, a combination of phenylephrine and ketorolac, is added to irrigating solution during cataract surgery or intraocular-lens replacement. The product maintains pupil size by reducing intraoperative miosis and also lowers postoperative ocular pain. One 4-mL vial is diluted for a single surgical patient.

Reported quarterly U.S. net sales total approximately USD 132.2 million for 2024 and USD 112.1 million for 2025, representing an estimated 15.2% decline. Revenue can vary with reimbursement, payer mix, distributor inventory, chargebacks, contracting, purchase timing, and realized net price, so sales cannot be converted reliably into treated procedures or vials.

OMIDRIA nevertheless provides the strongest publicly measurable branded revenue stream associated with pupil management. Clinical trials involving 821 patients found that fewer than one in ten treated patients developed a pupil diameter below 6 millimeters during surgery, compared with approximately four in ten placebo recipients.

 

Permanent Mydriasis Surgery Remains Concentrated in Specialist Centers

Pupilloplasty and iris reconstruction treat permanently enlarged, irregular, or displaced pupils caused by trauma, surgery, or iris-sphincter damage. Common techniques include iris cerclage, focal sphincter suturing, sector repair, the Siepser slip-knot method, and fixation of detached iris tissue. Extensive tissue loss may require implantation of an artificial iris.

CMS hospital-outpatient ratesetting data confirm the low procedural volume. CPT 66682, the closest billing-code proxy for iris-suture pupilloplasty, recorded 65 claims in full-year 2022, 48 claims during January–September 2023, and 64 preliminary claims during January–September 2025. These figures cover Medicare hospital-outpatient services only and include iris repairs performed for conditions other than permanent mydriasis.

CPT 66680, which covers broader iris or ciliary-body repair, recorded 35 claims during January–September 2025. CPT 66683, introduced as a Category I code for artificial iris implantation in 2025, recorded 25 hospital-outpatient claims during the same period.

A retrospective series of 70 eyes treated for traumatic or postoperative iris damage found that 35 eyes, or 50%, had mydriasis. Trauma accounted for 80% of cases, while 80% of pupilloplasty procedures were combined with another ophthalmic operation. The Siepser slip-knot technique was used in 60 eyes, or 86%, and lasso or cerclage suturing was used in four eyes. Specialist surgeons commonly perform iris repair as part of broader ocular reconstruction rather than as an isolated operation.

 

Artificial Iris Implantation Addresses Severe Iris Defects

The FDA approved the CustomFlex Artificial Iris in May 2018 for children and adults with full or partial aniridia caused by congenital abnormalities, acquired defects, or other conditions. Eligible patients extend beyond those with permanently dilated pupils.

HumanOptics reports more than 7,500 artificial iris implantations worldwide since the first procedure in 2002. The figure represents a manufacturer-reported cumulative installed base rather than annual sales or audited procedure volume.

Artificial iris procedures carry high value per case but remain limited by individualized manufacturing, specialist surgical expertise, complex ocular anatomy, reimbursement review, and the small number of eligible patients.

Iris hooks and pupil-expansion rings belong outside the permanent-mydriasis segment. Cataract surgeons use these devices temporarily to enlarge inadequately dilated pupils, while pupilloplasty reduces an abnormally large pupil.

 

Provider Stocking and Patient Payment Control Reversal-Drug Adoption

The United States had approximately 47,800 optometrist jobs in 2024, with 54% based in optometry offices and another 16% in physicians’ offices. Thousands of independently managed practices create a fragmented account base for diagnostic mydriatics and post-dilation reversal products.

Practices can order RYZUMVI through authorized distributors, stock single-patient-use vials, identify suitable patients, collect payment, and administer the product after dilation. Viatris must first persuade the practice to adopt the product, after which clinical staff must convert eligible patients at the point of care.

Large ophthalmology and optometry networks can spread training, inventory, and administration costs across more encounters. Independent practices face greater exposure to slow inventory turnover and inconsistent patient acceptance.

Hospitals and ambulatory surgery centers follow a different purchasing process. Formulary review, surgeon preference, reimbursement, procedural economics, and contracting influence the use of products such as OMIDRIA and reconstructive devices.

 

Phentolamine Development Extends Beyond Dilation Reversal

Opus Genetics and Viatris are also developing phentolamine ophthalmic solution for presbyopia and low-light vision disturbances after keratorefractive surgery. Company filings now refer to the asset by its generic formulation rather than the earlier Nyxol development name.

VEGA-3 enrolled 569 participants across 36 U.S. sites. At 12 hours after dosing on Day 8, 27.2% of treated participants achieved at least a 15-letter improvement in binocular distance-corrected near visual acuity without a clinically meaningful loss in distance vision, compared with 11.5% receiving placebo.

Viatris filed a supplemental New Drug Application in December 2025. The FDA accepted the submission and assigned an action date of October 17, 2026.

Approval in presbyopia would move phentolamine from episodic post-examination use into recurring treatment. Commercial competition would also increase because approved miotic products and other late-stage presbyopia therapies already target the same patient population.

 

Pharmaceutical Products Hold an Estimated 95% Share by Treatment Type

Pharmaceutical products generated an estimated 95% of 2025 revenue through diagnostic mydriatics, procedure-linked OMIDRIA use, and early RYZUMVI adoption. Pupilloplasty, iris reconstruction, and artificial iris implantation accounted for approximately 4%, reflecting high value per case but very low specialist volume. Tinted contact lenses and other symptom-management products contributed about 1%. Recurring examinations and cataract procedures will keep drugs dominant despite improving surgical coding and access to customized iris prostheses.

 

Dilation-Inducing Drugs Account for an Estimated 52% Share by Product Function

Diagnostic mydriatics and cycloplegics held an estimated 52% share through routine tropicamide, phenylephrine, cyclopentolate, and atropine use. Intraoperative dilation-maintenance products represented approximately 44%, supported by OMIDRIA’s higher revenue per procedure. Reversal agents accounted for about 4% after the recent RYZUMVI launch. Post-dilation reversal has the strongest expansion potential, but cash-pay dependence, practice stocking, natural recovery, and possible generic entry limit near-term penetration.

 

Eye Clinics Generate an Estimated 49% Share by End User

Optometry and ophthalmology clinics accounted for an estimated 49% of revenue through repeated examinations, provider-stocked mydriatics, and dilation-reversal treatment. Ambulatory surgery centers represented approximately 38%, driven by cataract surgery and intraoperative pupil-maintenance products. Hospitals contributed the remaining 13% through complex ophthalmic procedures, ocular trauma, pupilloplasty, and artificial iris implantation. Clinics lead in administration frequency, while surgical facilities generate higher revenue per treated encounter.

 

Competitive Landscape

Viatris leads the U.S. dilation-reversal segment through RYZUMVI, while Opus Genetics receives development milestones and tiered royalties. Their collaboration also covers phentolamine development for presbyopia and low-light visual disturbances across most global territories.

Rayner Surgical controls OMIDRIA commercialization and holds the strongest publicly measurable branded sales position in procedure-linked pupil management. Generic tropicamide, phenylephrine, cyclopentolate, and atropine suppliers compete through price, distributor availability, packaging, institutional contracts, and supply reliability.

MYDCOMBI established the regulatory viability of fixed-dose microdosed ophthalmic delivery, but weak sales and discontinued commercialization reduced its competitive presence. Conventional drops remain difficult to displace when providers already purchase low-cost products through established channels.

Sandoz is the most visible prospective RYZUMVI competitor. The company filed an abbreviated application with a Paragraph IV patent challenge, leading Opus Genetics and Viatris to initiate infringement litigation in March 2025. Trial was scheduled for January 2027 as of the March 2026 filing. Generic entry could lower patient cost and expand utilization while reducing branded price, market share, and royalty income.

HumanOptics competes in reconstructive ophthalmology through the CustomFlex Artificial Iris. Pupilloplasty remains fragmented among specialist surgeons and hospitals, with competition centered on surgeon expertise, sutures, surgical instruments, customized implants, and access to complex anterior-segment care.

 

North America Leads the Verified Commercial Market

North America holds the strongest commercial position through approximately 100 million annual U.S. dilation events, nearly four million cataract procedures, established FDA approvals, large outpatient eye-care networks, branded procedural-drug sales, and an active cash-pay pathway for reversal treatment.

International examination volume does not automatically create a commercial reversal market. Suppliers require country-specific regulatory approval, distributor access, provider adoption, pricing acceptance, and either reimbursement or a viable patient-pay model.

 

Market Outlook

Mydriasis treatment is expanding beyond low-cost diagnostic drops into products that manage pupil size before, during, and after ophthalmic care. OMIDRIA demonstrates the revenue potential of a branded product linked to reimbursed cataract procedures. RYZUMVI addresses a different buyer decision because patients must pay for convenience after the diagnostic value of dilation has already been obtained.

Routine diagnostic dilation will continue to generate the largest treatment volume, although generic pricing limits revenue growth. Cataract surgery provides the strongest established revenue per event. Post-dilation reversal can expand among working adults, caregivers, drivers, screen-dependent patients, and people receiving repeated retinal examinations, provided practices stock the product and patients accept the price.

Pupilloplasty and artificial iris implantation will remain specialist services. CMS claims and clinical series indicate that these procedures are uncommon and frequently performed with cataract surgery, vitrectomy, corneal repair, or intraocular-lens reconstruction.

RYZUMVI account penetration, the October 17, 2026 FDA decision for phentolamine in presbyopia, OMIDRIA reimbursement, generic patent litigation, and provider-level economics will determine near-term competition. Suppliers able to improve surgical stability, shorten post-examination disruption, simplify administration, and fit existing purchasing workflows will secure the strongest positions.

 

Mydriasis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 692.4 Million
Revenue Forecast in 2032	USD 1,019.3 Million
Overall Growth Rate	CAGR of 5.68% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Product Function, By Application, By End User, By Geography
By Treatment Type	Pharmaceutical Products, Surgical & Reconstructive Procedures, Symptom-Management Products
By Product Function	Dilation-Inducing Drugs, Intraoperative Dilation-Maintenance Products, Dilation-Reversal Agents, Iris Reconstruction & Artificial Iris Implants
By Application	Diagnostic Eye Examinations, Cataract & Intraocular-Lens Surgery, Retinal & Diabetic Eye Monitoring, Post-Dilation Reversal, Permanent Mydriasis & Iris-Defect Reconstruction
By End User	Optometry Clinics, Ophthalmology Clinics, Ambulatory Surgical Centers, Hospitals
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	High volume of routine pharmacologic eye dilations Growth in cataract-surgery procedures Increasing adoption of post-dilation reversal treatment
Customization Option	Available upon request